Innovative reporting engines from StatFinn Ltd The fastest way to conclusion www.statfinn.fi www.statfinn.fi
Market Opportunity The Drug Deveopment Challenge Pharma has, on average, 12 patent protected years to recover massive amount of development costs (up to $2 billion) and to make profit. For a blockbuster drug each day saved in development means one extra day in market which is extra $15 million in sales. Consequently drug developing companies are desperate for finding tools and services that could shorten the development phase and time-to-market. 3.5 years 4 years 2-4 years $ 350 million $ 100 million $ 150 million Preclinical Exploratory Full Discovery Launch Development Development Development Phase I Phase II Phase III Phase IV Preclinical Clinical The fastest way to conclusion
Solution Innovative ApproachStatFinn provides data management and statistical reporting services to pharmaceutical industry.StatFinn’s eBESTreports is first-in-market reporting application for the time and resources consuming reporting phase of clinical trials. eBESTreports is available 24-7 as a cloud service and reduce the reporting time remarkably. The fastest way to conclusion
Business Model From expert services to productized services eBESTreports is used as arrow-head product to increase revenues of StatFinn’s traditional services. eBESTreports is highly profitable needing minimal resources from StatFinn. CRO Products eBESTreports are easily scaled up with additional service products. Target sectors Biotech, Pharma and Custom clinical CROs companies. CRO companies act as distributors INITIAL SALES while using the tool to Biotech and Pharma. The fastest way to conclusion
Markets Growing quickly The total CRO market is $35 billion by 2015. Annual growth of 11%. Market potential for StatFinn services is $1 billion. The fastest way to conclusion
Financial Projections Year 2016Revenue 10 M€ Products 25% People 35 Customers: Increases sales Finland 25, 15 Pharma, 70 Biotechs, of all services Switzerland 5, 10 CROs UK/Germany 5 Profit 30% International business 80% Business acquisitions 16.000.000 € 14.000.000 € Sales 12.000.000 € 10.000.000 € Profit 8.000.000 € 6.000.000 € 4.000.000 € 2.000.000 € 0€ 2011 2012 2013 2014 2015 2016 2017 The fastest way to conclusion
The Team The Company Pekka Heikkilä (15%), Pasi Korhonen (60%), CEO, Member of Board Founder, CSO, Chair of Board Business and Scientific expertise Entrepreneur and Scientific expertise Novartis Pharma Orion Pharma Clinical Research Service Turku EPID Research, University of Turku Marko Suomela (20%), Member of Sanna Ström, Quality Manager Board Data Management and Process expertise Financial expertise Clinical Research Services Turku Forex, NestleTuomas Kemppainen, Expert Statistician Elina Niskanen, Marketing and Sales DirectorScientific and Process expertise Marketing and sales expertiseNovartis Pharma, 4Pharma Galanthia, admescope, John Wiley & Sons StatFinn Ltd Founded in 2005 and has been profitable ever since. Providing data management and statistical reporting services for various sectors in life science. The company has 12 employees at two offices in Turku and in Helsinki. The fastest way to conclusion
Money Talk The investment opportunityStatFinn is seeking for 3 million euros investment for organic growth and developing new report engines (eBESTpk, eBESTstab, etc.) to strengthen service portfolio a company acquisition to expand market presence, and to increase resources and revenues a company acquisition to expand service portfolio to fulfil the market demand and access wider markets and dealsPrevious financial rounds Centre for Economic Development, Transport and the Environment: 50 k€ Product development by TEKES in 2010: 100 k€ NIY by TEKES in 2011: 250 k€ (NIY1) 750 k€ (NIY2) The fastest way to conclusion
Money Talk The investment opportunity Exit in 3 to 5 years with trade sale or IPO Unique products with clear customer benefits in growing markets which guarantees competitive advantage and revenue with high profit. Experienced team with supplementary skill combination. Proven business model with profitable business since its foundation. Reduced investment risk with successful grants approval in investments for internationalization and development activities. The fastest way to conclusion
Thank You Contact Pekka Heikkilä, CEO email@example.com +358 50 321 6006Linnankatu 9b A1, 20110 Turku The fastest way to conclusion
A particular slide catching your eye?
Clipping is a handy way to collect important slides you want to go back to later.